Allogene Therapeutics Gains FDA RMAT and Fast Track Status for Cema-Cel in First-Line Large B-Cell Lymphoma
Thursday, July 30, 2026
Allogene Therapeutics has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the US Food and Drug Administration (FDA) for its investigational allogeneic CAR T therapy, cemacabtagene ansegedleucel (cema-cel). The designations apply to adult patients with large B-cell lymphoma (LBCL) who remain in complete or partial response after first-line treatment but test positive for minimal residual disease (MRD). The regulatory status is expected to support closer interaction with the FDA and help accelerate the therapy’s clinical development and review.
Cema-cel is currently being evaluated in the pivotal ALPHA3 clinical trial as a first-line consolidation treatment for patients with LBCL who face a high risk of relapse. The study uses Natera’s CLARITY MRD assay to identify patients who are in remission but remain at risk of disease recurrence following first-line chemoimmunotherapy. Eligible patients are randomly assigned to receive either a single dose of cema-cel or standard observation, with outcomes compared between both groups.
The FDA granted the RMAT designation after reviewing interim data from the ongoing ALPHA3 trial. At the planned data cut-off, 58.3% of patients treated with cema-cel achieved MRD negativity, compared with 16.7% of patients receiving observation. This resulted in a 41.6% absolute improvement in MRD clearance. Previous clinical evidence suggests that improvements of 25% to 30% in MRD clearance may translate into meaningful clinical benefits.
The interim safety findings showed that cema-cel was well tolerated. No treatment-related serious adverse events were reported, and there were no cases of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, graft-versus-host disease or severe infections. No patients required hospitalisation due to treatment-related side effects, and no preventive or treatment-related use of tocilizumab or steroids was necessary.
RMAT designation is intended to speed up the development and review of regenerative medicine therapies that show the potential to address serious or life-threatening conditions with unmet medical needs. The additional Fast Track designation may also allow for a more efficient regulatory review process, including potential rolling and priority review if the required criteria are met.
Source: globenewswire.com
